Stocktoria
Wave Life Sciences Ltd. WVE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-11-11
Wave Life Sciences Ltd. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -504.1% | -101.9% | -60.0% | -4459.3% | -310.1% |
| Net margin | -478.3% | -89.6% | -50.8% | -4434.7% | -298.4% |
| FCF margin | -440.5% | -140.3% | -18.1% | -3539.1% | -218.6% |
| Return on assets | -32.0% | -27.5% | -20.9% | -110.5% | -59.1% |
| Return on equity | -39.4% | -46.3% | -145.1% | 358.9% | -376.2% |
| Current ratio | 6.47 | 2.89 | 1.26 | 1.38 | 2.53 |
| Revenue growth | -60.5% | -4.4% | 3005.1% | -91.1% | 104.0% |
Source: SEC EDGAR filings · CIK 0001631574 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.